Key takeaways for Pennsylvania
- • No GLP-1 is FDA-labeled for prediabetes — use is off-label.
- • Eligibility may still apply if BMI 30+ or 27+ with comorbidity (Wegovy/Zepbound).
- • Roughly 80-95% of prediabetic adults revert to normoglycemia in major trials.
- • Pennsylvania Medical Assistance (HealthChoices) coverage rules apply for Prediabetes patients in Pennsylvania — see Medicaid section below.
- • 13 GLP-1 telehealth providers available nationwide.
Why GLP-1 medications for Prediabetes
No GLP-1 drug carries an FDA prediabetes indication. However, in obese prediabetic adults, Wegovy and Zepbound are approved on the basis of BMI/comorbidity criteria, and both have been shown in trial post-hoc analyses to convert prediabetes back to normoglycemia in the majority of treated patients. Evidence grade: B (extrapolation from RCT subgroups). Lifestyle therapy and metformin remain first-line per ADA. GLP-1 use specifically for prediabetes is off-label and should be discussed with a physician.
Pennsylvania-specific context
Pennsylvania has telehealth access concentrated in Philadelphia, Pittsburgh, Allentown metros, with additional reach to Erie and Reading. UPMC, Penn Medicine, Children's Hospital of Philadelphia is the largest in-state academic medical center for endocrine + obesity-medicine specialty consults. The state health authority publishes prescribing + coverage updates at www.health.pa.gov.
Pennsylvaniatelehealth & pricing rules
- • Pennsylvania permits audio-only and asynchronous telehealth visits for GLP-1 care.
- • Pennsylvania allows new-patient telehealth prescribing without a prior in-person visit.
- • Typical cash GLP-1 price in Pennsylvania: ~$245/mo (compounded options often lower, brand higher).